A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

The main focus right now in the myeloma paradigm of treatment is, okay, how do we harness the best power of CAR-T? We're doing it later in the treatment of myeloma. We've tried to move it earlier, and ...

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say ...

Films like Strong: Living with Multiple Myeloma are essential. Multiple Myeloma is not exactly high on the list of diseases ...

which showed that D-VRd led to significant improvement in PFS compared with VRd alone in patients with newly diagnosed multiple myeloma eligible for stem cell transplant, and led to the regimen's ...

The mother of a seven-year-old with a life-threatening blood disorder says despite treatments being the same as cancer, they ...

The future is bright for our bone marrow transplant program,” Dr. Hana Safah said. "We look forward to advancing blood cancer ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...